A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma is a research paper published in The Oncologist (2024). On theSindex it has a DataRank of 0.269. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: T32 CA009172
NCATS NIH HHS
Grant: UL1 TR001863
National Institutes of Health
Grant: 2P50CA101942-16
DF/HCC Kidney Cancer SPORE
National Institutes of Health
Grant: 5P30CA006516-56
Dana-Farber/Harvard Cancer Center
Bristol-Myers Squibb
Bristol-Myers Squibb
Fields of Study
MeSH Terms
Keywords